AbSci Corp (ABSI) News
Filter ABSI News Items
ABSI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABSI News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ABSI News From Around the Web
Below are the latest news stories about ABSCI CORP that investors may wish to consider to help them evaluate ABSI as an investment opportunity.
Absci, Owkin announce partnership to bring together AI platformsAbsci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived |
Advanced Micro Devices (AMD) Invests in Absci for AI-Driven Drug Discovery with High-Performance Computing SolutionsWe recently published a list of 13 AI News and Ratings You Probably Missed. In this article, we are going to take a look at where Advanced Micro Devices, Inc. (NASDAQ:AMD) stands against other AI stocks. As per a CNBC report, in 2025, significant changes are expected in global AI regulation, especially in the U.S., […] |
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug DiscoveryCollaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeuticsVANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership |
AMD Shares Slide as HSBC Downgrades Stock Over Nvidia Concerns; Absci Collaboration AnnouncedHSBC downgraded AMD to "Reduce," citing weaker AI GPU competitiveness and supply chain issues. |
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug DiscoveryAI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities. The partnership will leverage AMD Instinct accelerators and ROCm software to support Absci’s advanced de novo antibody design models. The deal also includes a $20 million private investment in public equity (PIPE) by AMD, underscoring the ris |
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm SoftwareVANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci's advanced de novo |
AMD Invests in Drug-Discovery Company Absci in Push to Sell AI ChipsThe $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries. |
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal HealthCollaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applicationsVANCOUVER, Wash. and BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Invetx, a pioneer in protein-based therapeutics for animal health, today announced a strategic partnership to harness Absci’s AI Drug Creation models to create an innovative Half-Lif |
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceVANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Absci management is scheduled to present on Wednesday, January 15th at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company’s in |
Why Absci Corporation (ABSI) Is One of the Best Biotech Penny Stocks to Invest in Now?We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from lower […] |